Seizures are present in over 90% of infants and children with Wolf-Hirschhorn syndrome (WHS). When present, they significantly affect quality of life. The goal of this study was to use caregiver reports to describe the comparative efficacies of commonly used antiepileptic medications in a large population of individuals with WHS. A web-based, confidential caregiver survey was developed to capture seizure semiology and a chronologic record of seizure treatments as well as responses to each treatment. Adverse events for each drug were also cataloged. We received 141 complete survey responses (47% response rate) describing the seizures of individuals ranging in age from 4 months to 61 years (90 females: 51 males). Using the Early Childhood Epilepsy Severity Scale (E-Chess), WHS-associated seizures are demonstrably severe regardless of deletion size. The best-performing antiepileptic drugs (AEDs) for controlling seizures in this cohort were broad spectrum drugs clobazam, levetiracetam, and lamotrigine; whereas, the three commonly used carboxamide class drugs: carbamazepine, phenytoin, and oxcarbazepine, were reported to have little effect on, or even exacerbate, seizures. The carboxamide class drugs, along with phenobarbital and topiramate, were also associated with the highest rate of intolerance due to cooccurrence of adverse events. Levetiracetam, clobazam, and clonazepam demonstrated higher tolerability and comparatively less severe adverse events (Wilcoxon rank sum comparison between performance of levetiracetam and carboxamide class drugs gives a p b 0.0001 after multiple comparison adjustment). This is the largest survey to date assessing WHS seizures. This study design is susceptible to possible bias, as the data are largely drawn from caregiver report and investigators had limited access to medical records. Despite this, our data suggest that the genetic etiology of seizures, together with an accurate electroclinical delineation, are important components of drug selection, even in contiguous gene syndromes which may have complex seizure etiologies.
Introduction
Wolf-Hirschhorn syndrome (WHS; Online Mendelian Inheritance in Man (OMIM) #194190) is a rare contiguous gene deletion syndrome affecting the terminal region of chromosome human chromosome 4, petite arm (4p) [1] . Epilepsy is a serious neurologic challenge for over 90% of individuals with WHS, presenting in early childhood and potentially affecting cognitive development [2] . A previous study involving 87 individuals with WHS determined that seizure types most commonly experienced are generalized tonic-clonic, tonic or clonic, and complex partial [3] . Atypical absences with a myoclonic component occur in one-third of children [3] . Approximately 40-50% of individuals with WHS experience status epilepticus with prolonged, life-threatening seizures [1, 3] .
There are now over 30 FDA-approved drugs for seizure control. Currently, seizure types and electroclinical presentations play significant roles in driving drug selection for epilepsy treatment [4] , while genetic etiology is only beginning to be considered a relevant factor [5] . As advances in genetics continue to contribute to the understanding of the underlying molecular etiology of epilepsy, studies demonstrating efficacies of one drug over another based on specific genetic causes become increasingly important [6] .
Given the complex seizure semiology of WHS individuals, we aimed to understand whether certain drugs confer better overall seizure control than others. We developed, tested, and implemented a web-based confidential survey which was distributed to approximately 300 families in the 4p-Support Group. The survey was designed to capture caregiver-observed seizure types [7] and presentations, the antiepileptic drugs (AEDs) used to control seizures in the chronological order in which they were taken, and the individuals' responses to these drugs in the form of seizure control and adverse events while on the drug. Here, we present an analysis of the survey results, which indicates that certain drugs currently in use in this population demonstrate significantly better performance metrics in controlling seizures than others, despite the complex seizure presentation of this disorder.
Methods

Cohort
A study cohort was recruited from approximately 300 families who are members of the 4p-Support Group. This group is US-based, but does also include a minority of families from Europe and Asia. Inclusion criteria were the following: 1) the individual must have a diagnosis of WHS; 2) the diagnosis must have been confirmed by clinical cytogenetic or molecular testing consisting of one or more of the following: positive fluorescence in situ hybridization (FISH), positive karyotype, and positive cytogenomic microarray; and 3) the individual must have experienced at least one seizure and have received at least one type of seizure treatment. Exclusion criteria were the following: 1) no seizures were experienced despite having a WHS diagnosis, and 2) lack of molecular testing confirming a WHS diagnosis. In all cases, the survey was completed by a caregiver who was familiar with the affected individual's seizures and responses to treatments. When medical records were available (N = 22), they were used to confirm caregiver answers to survey questions. Families also submitted copies of the molecular diagnostic reports when available (N = 50).
Survey design
A survey to capture seizure phenotypes and treatment responses was developed in accordance with previously published survey studies designed for similar purposes for both human chromosome 15, long arm (15q) duplication syndrome and Angelman syndrome (AS) [8, 9] . The survey consisted of three parts: 1) a demographics section to collect information including name of WHS-affected individual, age, gender, and genetic testing methods used to confirm diagnosis; 2) a seizure history section to collect information such as age of seizure onset, types of seizures experienced [7] , and types seizure triggers; and 3) a seizure treatments and treatment responses section to collect information concerning treatments tried, and responses to each treatment, in chronological order of use (see Supplemental material for a complete list of the survey questions). Reported treatment responses were scored on a 5 point scale: 5 = complete seizure control (as defined by an absence of seizures for 6 months while on the treatment), 4 = 50% or greater reduction in seizure frequency, 3 = less than 50% reduction in seizure frequency, 2 = no change in seizure frequency or a response of "I don't know," and 1 = increase frequency of seizures or treatment had to be discontinued due to intolerable cooccurrence of adverse events.
To improve the utility and accuracy of the survey, a focus group of four parent volunteers whose children met inclusion criteria and a research scientist (LM) were assembled to discuss each question in a private cognitive interview with each parent. The survey was revised in accordance with feedback from the interviews and edited for clarity and brevity (see Supplemental information). The final survey was made available through the Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant platform REDCap (Research Electronic Data Capture; https://catalyst.harvard.edu/services/redcap/).
Seizure severity scoring
Seizure severities were classified using a modified Early Childhood Epilepsy Severity Scale (E-Chess). Scores were calculated following the method of the original E-Chess paper [10] except as described below. In short, scoring was calculated as follows for the four severity indices: time period over which seizures occur (1 point = less than a month, 2 points = 1-6 months, 3 points = more than 6 months); number of seizure types (1 point = one seizure type, 2 points = two seizure types, 3 points = 3 or more seizure types); number of anticonvulsants used (0 points = none, 2 points = one or two anticonvulsants used, 3 points = more than two used); and response to treatment (1 point = complete cessation of seizures, 2 points = partial cessation of seizures, 3 points = no improvement or worsening of seizures). Two indices of the six-point scale were omitted, namely frequency of seizures (weekly, daily, more than daily) and occurrence/duration of status seizures. These components were omitted for the following reasons: seizure frequency varies widely, even within the same individual, and varies depending on age in the WHS group. Since our cohort had a very wide age range, this variable was unlikely to be contributory. Regarding the status seizure component, Humphrey et al. reported that this component was not statistically predictive of severity while the other five indicators were, and dropped the component from further analyses in their statistical modeling of seizure severity [10] .
The study, recruitment materials and methods, participant consent forms, and survey questions were approved by the University of Utah Institutional Review Board (IRB #00064655).
Statistical analyses
Calculations and statistical analyses were performed using Excel for data assembly, scoring, basic calculations (e.g., mean, standard error, median, quartile calculations), and for generating bar graphs, charts, tables, histograms, and box plots. For statistical hypothesis tests, the statistical software package Statistical Analysis Software (SAS) 9.4 was used. Because our data either take discrete values or are highly skewed, we used the Wilcoxon rank sum and Kruskal-Wallis tests to compare outcomes between groups, as indicated in the text. A p value of 0.05 or less was taken to be significant, except in cases of multiple testing, in which case Bonferroni correction was applied to the significance test, as indicated in the text. Drugs were reported as being used as monotherapy or as combinations; however, because of our small sample size (N = 141) as compared with the number of drugs (N = 22), we performed analyses on each drug as though the drug were not used in combination in order to observe overall efficacy on an individual drug basis.
Results
One hundred and forty-three surveys were completed and received from the estimated 300 families in the 4p-Support Group, a nonprofit organization for families of individuals with deletions on 4p which is based in the USA but with worldwide membership. One participant's responses were excluded from analysis, and one participant's responses were modified: 1) an individual, whose genetic analyses were negative by karyotype and FISH, but who nevertheless had received a clinical diagnosis of WHS, was later found to not have a deletion on 4p through high resolution chromosomal microarray analysis and was therefore excluded from the study; and 2) a second individual with WHS had two parental participants who submit independent survey answers on the same child. Their answers were verified by comparison to one another, and then combined as one entry. The final total number of participants was therefore 141, with a response rate of 47%. The demographical information on our cohort is shown in Table 1 .
Seizure severity in WHS
To establish the overall seizure severity phenotype of our cohort, we used a modified E-Chess score adapted from Humphrey et al. [10] . This objective measure of seizure severity at 12 months was shown to be robust and predictive of the E-Chess score at 24 and 36 months in a cohort of twenty infants with a diagnosis of tuberous sclerosis [10] . The method assigns points to four contributory indicators (the time period over which seizures occurred, response to treatment, number of anticonvulsants used, and number of seizure types), with 0-3 points possible for the severity of each indicator, with 3 being the most severe, and a total of twelve possible points overall for the four categories (see Methods). Using this scale, we found that members of this cohort displayed high (N 6) seizure severity scores (mean = 8.63 ± 0.15 std err; median = 9.00).
Seizure severity tends to taper with age in WHS, with some individuals experiencing a complete cessation of seizures by their teenage years [3] . Consistent with this independent observation, we found that children in our cohort under 8 years of age (cohort median) exhibit higher E-Chess scores and therefore more seizure severity by this measure than individuals age 8 or older (p = 0.022, Wilcoxon rank sum; Supplemental Fig. S1 ).
Seizure semiology in WHS
Seizure onset occurred as early as the first day of life for one individual in our cohort or as late as 4 years old (Table 1 and Supplemental  Fig. S2 ). The majority of individuals presented with seizures by 1 year of age (Fig. S2) . Twelve percent (17/141) of individuals indicated having seizures associated with fever, and this association has been welldocumented in WHS [3] . In accordance with previously reported observations [3] , all seizure types [7] (absence, tonic-clonic, tonic, clonic, myoclonic, partial or focal motor, atonic, infantile spasms, as well as subclinical seizures) were observed in our cohort, with absence, tonic-clonic, and myoclonic seizures being most frequently observed (frequency of observed seizure types given in Supplementary  Table S2 ). Sixty percent of the cohort also reported experiencing status epilepticus of a duration lasting 30 min or more.
Seizure treatments
Participants (N = 141) provided information on the chronological order of antiseizure medications tried as well as whether they were used as monotherapy or in combinations. Overall, an average of three AEDs or combination of AEDs was tried with a range from 1 to 18 (Table 1 and Supplemental Fig. S3 ).
Forty-three individuals provided medical records containing chromosomal microarray genetic testing results from which deletion breakpoint information could be obtained. Based on these records, 26 individuals had "pure" terminal deletions (e.g., no other clinically reportable, rare copy number variants (CNVs) were found using whole genome microarray). To eliminate the possibility of significant enhancer or suppressor effects from additional rare CNVs, we limited our analyses to the deletion sizes and AED data from these 26 individuals to ask whether deletion size correlated with a larger number of AEDs tried for seizure control. Using this dataset, we find that there is a correlation between larger deletion sizes and a larger number of consecutive trials of AEDs reported [11, 12] (Fig. 1 ; p = 0.0272 Kruskal-Wallis test).
Participants reported the response to each AED or combination of AEDs by selecting an answer from seven possible choices: 1) the drug gave complete control (defined as no seizures within the past 6 months), 2) 50% or greater reduction in seizures, 3) less than 50% reduction in seizures, 4) no change in seizure frequency, 5) "I don't know," 6) seizure frequency increased while on the AED(s), or 7) AED had to be discontinued for another reason. These answers were converted to numerical values using a scoring system to facilitate statistical analyses of drug responses (see Methods and Supplemental Table S3 for additional details).
To understand which AEDs are chosen as first-line drugs for seizure control in WHS, we tallied the frequency of use for each initial drug prescribed and found that the five most commonly prescribed first medications used as monotherapy or in combination were levetiracetam (both brand name Keppra as well as generic levetiracetam) (42.6%), phenobarbital (29.1%), valproic acid (17%), diazepam (7.8%), and carbamazepine (7.0%) ( Table 1) . We ranked each of the firstprescribed AEDs by efficacy score and found that four AEDs had an average effectiveness score of 4 or greater (out of a possible score of 5 for complete seizure control) while simultaneously having the highest retention rate (as measured by the fewest number of individuals having to move to a different drug). These were the following: clobazam, levetiracetam (both brand name Keppra and generic), and lamotrigine (gray-highlighted rows, Table 2 ). While topiramate had a high average effectiveness score (4.25 out of 5), it also had a low retention rate (75% of individuals starting on topiramate had to move on to a new drug due to intolerable effects).
To determine the overall effectiveness of AEDs used by our cohort, we scored responses to AEDs regardless of when during the chronological history of each patient they were taken, and again found that clobazam, levetiracetam, and lamotrigine were the highest scorers for seizure control. In contrast, a group of molecularly-related AEDs with sodium channels as their targets known as the carboxamide group, consisting of oxcarbazepine, phenytoin, and carbamazepine, clustered with the lowest overall effectiveness scores (Table 3) .
A case study in the literature has proposed that levetiracetam conferred excellent control of seizures in one individual with WHS [13] . Since levetiracetam was a first-choice drug for seizure control in our cohort (Table 1) and had a high number of uses for statistical comparison (N = 135, Table 3 ), we compared levetiracetam performance against the performance of the three worst-performing drugs, all members of the carboxamide group, to determine if there was indeed a statistical difference between the groups. We found that levetiracetam statistically performed better (p b 0.0001, Wilcoxon rank sum test after multiple test adjustment and Supplemental Fig. S4 ).
Adverse events
Separately from drug efficacy, participants reported any adverse events that coincided with the use of each drug or combination of drugs, and they indicated whether the adverse events were so intolerable that the drug was discontinued (Table 4 and Supplemental  Table S4 ). Although caregivers reported a high frequency of adverse events such as increased lethargy or increased irritability (for full list see Supplemental Table S4 ), some of these events resolved with time despite continued use of the drug, and it was difficult to determine whether the events were caused by the drug or merely correlated. In contrast, we also collected data on whether the drug was discontinued, and interpreted discontinuation to indicate that a medical provider warranted that the adverse event was likely linked to, or exacerbated by, the drug and not just coincidental with the drug use. By ranking the frequency of discontinuation (last column, Table 4 ), levetiracetam, diazepam, and clobazam, again showed good tolerability in individuals while the carboxamide group, along with topiramate and phenobarbital, showed comparatively poor tolerability.
Positive effects
Although we did not specifically ask for participant feedback on positive effects unrelated to seizure control, participants volunteered that clobazam, lamotrigine, and levetiracetam appeared to increase alertness, engagement, and development in eleven individuals (Table 5) . No such positive effects were reported for any of the carboxamide group drugs. However, it is difficult to say whether this absence of reported positive effects is significant since numbers were small and the Table 2 First-prescribed drugs for seizures: efficacy scores and retention rates. The table is ranked by descending efficacy scores, with 5 being complete control, 2 being lack of efficacy (no change in number of seizures), and 1 being an observed aggravation of seizures or intolerable effects while on the drug (Table S3) information on positive effects was volunteered and not formally collected.
Rescue medications are used during a seizure to bring about seizure cessation. Of the eighty-five individuals who reported having status epilepticus, 21 reported that one rescue medication seemed to have better efficacy than others. This drug was midazolam (Supplemental Table S5 ).
Discussion
Other studies that correlate genetic etiology with drug response
This investigation contributes to the growing number of published studies that use a caregiver survey approach for assessing the efficacy of AEDs within a genetically well-defined population, e.g., studies involving seizure control for AS [9, 14] , 15q duplication syndrome [8] , Dravet syndrome (DS) [15] [16] [17] [18] , tuberous sclerosis [19] [20] [21] , and Rett syndrome [22] . While epilepsy in these conditions shares similar presentations involving multiple seizure phenotypes, each geneticallydefined group collectively responds differently to different AEDs. For example, the 15q duplication cohort responded better than anticipated to drugs that are typically used for focal seizures, i.e., carbamazepine and oxcarbazepine, despite the fact that individuals with 15q duplications present with generalized epilepsy seizure types [8] . The DS, AS, and WHS also present with generalized epilepsy types, such as tonic-clonic, tonic, clonic, and myoclonic types, but in contrast to the 15q duplication syndrome cohort, individuals from all three of these groups responded better to broad spectrum drugs levetiracetam, clobazam, and lamotrigine [16, 23] . Carbamazepine, oxcarbazepine, and phenytoin (the carboxamide group drugs) perform poorly for individuals with DS [16] and they also performed poorly for our WHS cohort. In our study, the carboxamide group drugs displayed reduced efficacy in controlling seizures than other drugs overall, and increased seizure activity in some patients. In addition, they also exhibited low retention rates because of cooccurring adverse events.
WHS seizures share similarities with DS seizures
In a previous genotype-phenotype correlation study, we mapped a candidate seizure susceptibility region at the terminal end of chromosome 4, which includes, among three other coding genes, a candidate gene phosphatidyl inositol (PI) glycan anchor biosynthesis protein G (PIGG) [24] . Autosomal recessive mutations in PIGG cause a form of congenital disorder of glycosylation which includes seizures as a common feature [25] . Mechanistically, PIGG and members of the PI-glycan anchor pathway are required for proper localization of sodium channel, voltagegated, type I, beta b (SCN1BB) (zebrafish homolog of human sodium voltage-gated channel beta subunit 1 (SCN1B)) in Rohon-Beard neurons of the zebrafish [26] . If an analogous regulatory relationship exists in humans, haploinsufficiency of PIGG may mechanistically link seizures in WHS to those of DS [27] . Seizures in DS are caused by loss of function mutations that can result in lowered expression, misfolding, truncation, and mislocalization sodium channel, voltage gated or voltage gated sodium channel (SCN)-family sodium channels [28] [29] [30] [31] . It has long been known that carboxamide group drugs should be avoided in DS because they target sodium channels [32, 33] . If SCN family sodium channel function or localization is compromised by haploinsufficiency of PIGG in WHS, it follows that the carboxamide group drugs should also be avoided in WHS. Our survey data supports such a recommendation, as well as confirms prior clinical observations [3] .
The need for antiepileptic treatments for WHS individuals
Despite the observation that seizures tend to taper off in frequency as individuals with WHS age, the modified E-Chess scoring of seizure severity determined that early in life seizures are severe. In addition, there were 5 individuals (out of 23) over the age of 20 years in our cohort for whom seizures were intractable despite the trial of up to 18 different AEDs, suggesting that WHS seizures, even with age-related improvement, are not always amenable to currently available treatments. The high rate of adverse events observed as well as low drug retention rates overall also underscores the needs for a new generation of drugs with higher tolerability and efficacy than those currently available. The impressive response rate to our survey from family members of the 4p-Support Group (47%, with about 60 surveys initiated within 24 h of survey release) likely reflects high degree of patient family interest in finding safe and effective treatments for seizures. Although anecdotal, comments on the observable improvements in cognitive, speech, and developmental trajectories of their affected family member with seizure control underscore the importance of achieving seizure control as completely and as early as possible.
Limitations and biases
Our study is not without limitations. All caregiver-reported experience studies share potential challenges in data fidelity and reproducibility, and they lack study controls. One study by Akman et al. [34] compared parent report to files of electroencephalogram (EEG)-video monitoring and found that seizures tend to be underreported by parents. There was also potential for selection bias based on 4p-Support Group membership, from which we drew our cohort, since not all Table 3 Overall AED effectiveness was calculated using all uses of each drug regardless of chronological order in which they were used. Antiepileptic drugs in this table are ranked in descending order of average efficacy score. Only those drugs with N N 15 uses are shown, since inconsistent responses to drugs with fewer than 15 uses were expected to lack statistical power. Best-performing drugs are highlighted in light gray; worst-performing drugs are highlighted in dark gray. Levetiracetam performance in seizure control was significantly better than the carboxamide group drugs' performance (oxcarbazepine, phenytoin, and carbamazepine) (p b 0.0001, two-sided Wilcoxon rank sum test).
Drug
Average efficacy score N (number of uses) > 15 families with an affected family member elect to join a support group. In addition, those families who experienced more challenges and had a more complex seizure history may have been dissuaded by the format of our questionnaire; participants had to fill out the same section for each drug tried, thus making the survey longer and more involved for participants whose seizure treatment history was more complex. Last, but not least, we should keep in mind the variations in the use of AEDs in different countries due to differences in accessibility and clinical training. Given these limitations and biases, the observations set forth in this study need to be confirmed using an appropriately sized clinical research study with carefully selected controls.
Conclusion
This study represents the largest one assessing caregiver-reported seizure presentations and seizure treatment responses in WHS to date. Levetiracetam, a broad spectrum anticonvulsant that has been previously suggested as an efficacious drug in WHS [13] , significantly outperforms carboxamide group drugs (Tables 3-5 , and accompanying statistics). Furthermore, clobazam and levetiracetam emerged with the best seizure control profiles, in terms of both efficacy and high retention rates. These drugs do not share the same targets nor mechanisms of action, and therefore represent alternatives should the patient require an Table 4 Adverse events. Each adverse event reported by participants was recorded and scored as a single event while on the drug, even if the drug reaction or event resolved with time (as in allergic reactions, lethargy, or other event). The table is presented by frequency of intolerability in ascending order (last column of table), as represented by the frequency that the adverse event was the reason it was discontinued. The most highly efficacious drugs from Table 3 are highlighted in light gray, and the least efficacious drugs from Table 3 
